English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Background  To investigate whether the incorporation of  18 FDG-PET into the automatic treatment planning process may be able to decrease the dose to active bone marrow (BM) for locally advanced anal cancer patients undergoing concurrent chemo-radiation (CHT-RT).    Methods  Ten patients with locally advanced anal cancer were selected. Bone marrow within the pelvis was outlined as the whole outer contour of pelvic bones or employing  18 FDG-PET to identify active BM within osseous structures. Four treatment planning solutions were employed with different automatic optimization approaches toward bone marrow. Plan A used iliac crests for optimization as per RTOG 05–29 trial; plan B accounted for all pelvic BM as outlined by the outer surface of external osseous structures; plan C took into account both active and inactive BM as defined using  18 FDG-PET; plan D accounted only for the active BM subregions outlined with  18 FDG-PET. Dose received by active bone marrow within the pelvic ( ACT PBM) and in different subregions such as lumbar-sacral ( ACT LSBM), iliac ( ACT IBM) and lower pelvis ( ACT LPBM) bone marrow was analyzed.    Results  A significant difference was found for  ACT PBM in terms of D mean  ( p  = 0.014) V 20  ( p  = 0.015), V 25  ( p  = 0.030), V 30  ( p  = 0.020), V 35  ( p  = 0.010) between Plan A and other plans. With respect to specific subsites, a significant difference was found for  ACT LSBM in terms of V 30  ( p  = 0.020)), V 35  ( p  = 0.010), V 40  ( p  = 0.050) between Plan A and other solutions. No significant difference was found with respect to the investigated parameters between Plan B,C and D. No significant dosimetric differences were found for  ACT LSPBM and  ACT IBM and inactive BM subregions within the pelvis between any plan solution.    Conclusions  Accounting for pelvic BM as a whole compared to iliac crests is able to decrease the dose to active bone marrow during the planning process of anal cancer patients treated with intensity-modulated radiotherapy. The same degree of reduction may be achieved optimizing on bone marrow either defined using the outer bone contour or through  18 FDG-PET imaging. The subset of patients with a benefit in terms of dose reduction to active BM through the inclusion of  18 FDG-PET in the planning process needs further investigation.

bmc cancer

Incorporating 18FDG-PET-defined pelvic active bone marrow in the automatic treatment planning process of anal cancer patients undergoing chemo-radiation